Blockchain Registration Transaction Record

Regentis GelrinC: A Game-Changer in Knee Cartilage Repair?

Regentis Biomaterials (RGNT) advances GelrinC, an off-the-shelf hydrogel for knee cartilage repair, with FDA trial enrollment over 50% and a 400% production yield boost.

This development matters because it could revolutionize treatment for the 472,500+ annual knee cartilage procedures in the U.S., offering a simpler, off-the-shelf regenerative option that avoids the complexity and cost of cell-based therapies. If approved, GelrinC may provide durable, long-term relief, reducing the need for repeat surgeries and improving patients' quality of life. For the healthcare system, a scalable, ready-to-use solution could lower costs and broaden access to effective cartilage repair.